Latest COMMODORE CAPITAL LP Stock Portfolio
COMMODORE CAPITAL LP Performance:
2025 Q1: -13.57%YTD: -13.57%2024: 23.22%
Performance for 2025 Q1 is -13.57%, and YTD is -13.57%, and 2024 is 23.22%.
About COMMODORE CAPITAL LP and 13F Hedge Fund Stock Holdings
COMMODORE CAPITAL LP is a hedge fund based in NEW YORK, NY. On 24-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $814.6 Millions. In it's latest 13F Holdings report, COMMODORE CAPITAL LP reported an equity portfolio of $1.4 Billions as of 31 Mar, 2025.
The top stock holdings of COMMODORE CAPITAL LP are MRUS, NUVL, . The fund has invested 13.9% of it's portfolio in MERUS N V and 9.7% of portfolio in NUVALENT INC.
The fund managers got completely rid off ABIVAX SA, THIRD HARMONIC BIO INC (THRD) and NKARTA INC (NKTX) stocks. They significantly reduced their stock positions in SOLENO THERAPEUTICS INC (SLNO), ALKERMES PLC (ALKS) and XENON PHARMACEUTICALS INC (XENE). COMMODORE CAPITAL LP opened new stock positions in AGIOS PHARMACEUTICALS INC (AGIO), CELLDEX THERAPEUTICS INC NEW (CLDX) and SOLID BIOSCIENCES INC (SLDB). The fund showed a lot of confidence in some stocks as they added substantially to SCHOLAR ROCK HLDG CORP (SRRK), CELCUITY INC (CELC) and VIRIDIAN THERAPEUTICS INC (VRDN).
The top stock holdings of COMMODORE CAPITAL LP are MRUS, NUVL, . The fund has invested 13.9% of it's portfolio in MERUS N V and 9.7% of portfolio in NUVALENT INC.
The fund managers got completely rid off ABIVAX SA, THIRD HARMONIC BIO INC (THRD) and NKARTA INC (NKTX) stocks. They significantly reduced their stock positions in SOLENO THERAPEUTICS INC (SLNO), ALKERMES PLC (ALKS) and XENON PHARMACEUTICALS INC (XENE). COMMODORE CAPITAL LP opened new stock positions in AGIOS PHARMACEUTICALS INC (AGIO), CELLDEX THERAPEUTICS INC NEW (CLDX) and SOLID BIOSCIENCES INC (SLDB). The fund showed a lot of confidence in some stocks as they added substantially to SCHOLAR ROCK HLDG CORP (SRRK), CELCUITY INC (CELC) and VIRIDIAN THERAPEUTICS INC (VRDN).
COMMODORE CAPITAL LP Annual Return Estimates Vs S&P 500
Our best estimate is that COMMODORE CAPITAL LP made a return of -13.57% in the last quarter. In trailing 12 months, it's portfolio return was -18.33%.
New Buys
| Ticker | $ Bought |
|---|---|
| agios pharmaceuticals inc | 64,020,500 |
| celldex therapeutics inc new | 58,080,000 |
| solid biosciences inc | 21,552,500 |
| tyra biosciences inc | 8,835,000 |
New stocks bought by COMMODORE CAPITAL LP
Additions
| Ticker | % Inc. |
|---|---|
| scholar rock hldg corp | 83.68 |
| celcuity inc | 73.91 |
| viridian therapeutics inc | 50.00 |
| nurix therapeutics inc | 32.63 |
| vera therapeutics inc | 30.8 |
| cogent biosciences inc | 29.23 |
| neurogene inc | 15.62 |
| merus n v | 15.45 |
Additions to existing portfolio by COMMODORE CAPITAL LP
Reductions
| Ticker | % Reduced |
|---|---|
| soleno therapeutics inc | -24.59 |
| alkermes plc | -15.22 |
| xenon pharmaceuticals inc | -15.15 |
| inhibikase therapeutics inc | -9.8 |
COMMODORE CAPITAL LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| abivax sa | -9,399,680 |
| helix acquisition corp ii | -5,250,000 |
| nkarta inc | -876,102 |
| third harmonic bio inc | -2,445,970 |
COMMODORE CAPITAL LP got rid off the above stocks
Sector Distribution
COMMODORE CAPITAL LP has about 86.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 86.2 |
| Others | 13.8 |
Market Cap. Distribution
COMMODORE CAPITAL LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 52.2 |
| SMALL-CAP | 31.6 |
| UNALLOCATED | 13.8 |
| MICRO-CAP | 1.2 |
| NANO-CAP | 1.1 |
Stocks belong to which Index?
About 49.7% of the stocks held by COMMODORE CAPITAL LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 50.3 |
| RUSSELL 2000 | 49.7 |
COMMODORE CAPITAL LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of COMMODORE CAPITAL LP
COMMODORE CAPITAL LP has 31 stocks in it's portfolio. About 65% of the portfolio is in top 10 stocks. PCVX proved to be the most loss making stock for the portfolio. SLNO was the most profitable stock for COMMODORE CAPITAL LP last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| MRUS | merus n v | 13.87 | 4,472,840 | 188,262,000 | added | 15.45 | ||
Historical Trend of MERUS N V Position Held By COMMODORE CAPITAL LPWhat % of Portfolio is MRUS?:Number of MRUS shares held:Change in No. of Shares Held: | ||||||||
| NUVL | nuvalent inc | 9.69 | 1,855,000 | 131,557,000 | added | 14.39 | ||
| enliven therapeutics inc | 6.78 | 4,675,000 | 92,004,000 | added | 11.18 | |||
| SLNO | soleno therapeutics inc | 6.06 | 1,150,000 | 82,167,500 | reduced | -24.59 | ||
| XENE | xenon pharmaceuticals inc | 5.75 | 2,325,000 | 78,003,800 | reduced | -15.15 | ||
| ALKS | alkermes plc | 4.74 | 1,950,000 | 64,389,000 | reduced | -15.22 | ||
| AGIO | agios pharmaceuticals inc | 4.72 | 2,185,000 | 64,020,500 | new | |||
| PCVX | vaxcyte inc | 4.59 | 1,650,000 | 62,304,000 | added | 1.54 | ||
| VERA | vera therapeutics inc | 4.53 | 2,561,780 | 61,534,000 | added | 30.8 | ||
| CLDX | celldex therapeutics inc new | 4.28 | 3,200,000 | 58,080,000 | new | |||
| SRRK | scholar rock hldg corp | 4.13 | 1,745,000 | 56,101,800 | added | 83.68 | ||
| COGT | cogent biosciences inc | 3.92 | 8,892,820 | 53,268,000 | added | 29.23 | ||
| VRDN | viridian therapeutics inc | 3.58 | 3,600,000 | 48,528,000 | added | 50.00 | ||
| NRIX | nurix therapeutics inc | 3.48 | 3,978,910 | 47,269,400 | added | 32.63 | ||
| CNTA | centessa pharmaceuticals plc | 2.51 | 2,367,580 | 34,045,800 | added | 6.72 | ||
| AGLE | spyre therapeutics inc | 2.36 | 1,988,080 | 32,077,700 | unchanged | 0.00 | ||
| PHVS | pharvaris n v | 2.21 | 1,911,430 | 30,009,500 | unchanged | 0.00 | ||
| MNMD | mind medicine mindmed inc | 1.95 | 4,525,000 | 26,471,200 | added | 5.03 | ||
| SLDB | solid biosciences inc | 1.59 | 5,825,000 | 21,552,500 | new | |||
| bright minds biosciences inc | 1.33 | 500,000 | 18,035,000 | unchanged | 0.00 | |||
